Hospital Clínic de Barcelona, University of Barcelona, Barcelona, 08036, Spain.
Complejo Hospitalario Universitario de Ourense, Ourense, 32005, Spain.
Future Oncol. 2022 May;18(14):1717-1731. doi: 10.2217/fon-2021-1639. Epub 2022 Feb 9.
This subanalysis of the CAVIDIOPAL study evaluated the impact of individualized management of breakthrough cancer pain (BTcP) with fentanyl on the quality of life (QoL) of advanced cancer patients in Spanish palliative care units. This was a prospective, observational, multicenter study. The European Organization for Research and Treatment of Cancer's QLQ-C30 questionnaire was used at baseline (V0) and visit 28 (V28). Ninety-five patients were mainly treated with 67-133 μg fentanyl, showing a notable reduction in intensity (visual analog scale: 8.0 [V0] to 4.6 [V28]), frequency and duration of BTcP episodes shortly after the first 1-2 weeks of treatment, with significantly improved QoL (global health status: 31.1 [V0] to 53.1 [V28]). Low-dose sublingual fentanyl effectively reduced BTcP in advanced cancer patients in palliative care units, significantly improving QoL. : NCT02840500 (ClinicalTrials.gov).
这项 CAVIDIOPAL 研究的亚分析评估了在西班牙姑息治疗病房中，使用芬太尼个体化管理爆发性癌痛（BTcP）对晚期癌症患者生活质量（QoL）的影响。这是一项前瞻性、观察性、多中心研究。在基线（V0）和第 28 次就诊（V28）时使用欧洲癌症研究与治疗组织的 EORTC QLQ-C30 问卷。95 名患者主要接受 67-133μg 芬太尼治疗，在治疗的最初 1-2 周后，BTcP 发作的强度（视觉模拟评分：8.0[V0]至 4.6[V28]）、频率和持续时间明显降低，生活质量显著改善（总体健康状况：31.1[V0]至 53.1[V28]）。低剂量舌下芬太尼可有效减轻姑息治疗病房中晚期癌症患者的 BTcP，显著改善 QoL。：NCT02840500（ClinicalTrials.gov）。
